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In Brief
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transmission is important for malaria
control. Plouffe et al. developed SaLSSA,
a one-step high-throughput assay to
screen for malaria transmission-blocking
activity. A large panel of known and new
small molecules was analyzed by
SaLSSA. This provides starting points for
the discovery and development of
transmission-blocking drugs.
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Preventing transmission is an important element of
malariacontrol.However,mostof thecurrentavailable
methods to assay for malaria transmission blocking
are relatively low throughput and cannot be applied
to large chemical libraries. We have developed
a high-throughput and cost-effective assay, the
Saponin-lysis Sexual Stage Assay (SaLSSA), for iden-
tifyingsmallmoleculeswith transmission-blockingca-
pacity. SaLSSA analysis of 13,983 unique compounds
uncovered that >90%ofwell-characterized antimalar-
ials, including endoperoxides and 4-aminoquinolines,
as well as compounds active against asexual blood
stages, lostmostof their killingactivitywhenparasites
developed intometabolicallyquiescent stageVgame-
tocytes. On the other hand, we identified compounds
with consistent low nanomolar transmission-blocking
activity, some of which showed cross-reactivity
against asexual blood and liver stages. The data
clearly emphasize substantial physiological differ-
ences between sexual and asexual parasites and pro-
vide a tool and starting points for the discovery and
development of transmission-blocking drugs.
INTRODUCTION
Malaria is a vector-borne disease caused by apicomplexan eu-
karyotic protozoa of the genus Plasmodium. The parasites
have a complex life cycle involving vertebrates and anopheline
mosquitoes. Their asexual replication and destruction of erythro-
cytes give rise to the symptoms of malaria, including fever and
chills. In response to cues that are not well understood, a subset114 Cell Host & Microbe 19, 114–126, January 13, 2016 ª2016 The Aof asexual parasites differentiate into male and female gameto-
cytes (Sinden, 1983), a process that takes 8–12 days in
P. falciparum (Sinden, 2009). During this period, the parasites
metabolize the host red cell hemoglobin (Hanssen et al., 2012),
while progressing through five morphologically distinct stages
that can be identified by light microscopy (Carter and Miller,
1979). Commitment to sexual development occurs well before
parasites showmorphological changes, andmale and female ga-
metocytes are produced at a ratio of 1 to 3–5 (Gbotosho et al.,
2011; Robert et al., 2003) with females maturing slightly later
(Bounkeua et al., 2010). In the human body, immature gameto-
cytes sequester in different host tissues (Rogers et al., 2000)
and emerge only when fully mature. An infected individual may
carry gametocytes for up to 55 days (Bousema et al., 2010), and
maturegametocytesare theonly form that cansurvive in themos-
quito midgut, mate, undergo meiosis, and give rise to the next
generation of parasites to be transmitted to a new human host.
Current first-line treatment of falciparummalaria is artemisinin
combination therapies (ACTs) (WHO, 2015), which do not block
transmission. Follow-up treatment with 8-aminoquinolines like
primaquine or tafenoquine is needed to block transmission (Ezie-
fula et al., 2014). However, 8-aminoquinolines can be toxic to in-
dividuals with glucose-6-phosphate dehydrogenase deficiency,
a genetic condition with a high prevalence in malaria-endemic
regions (Luzzatto, 1979).
Even though assays are available to detect compounds with
transmission-blocking potential (Adjalley et al., 2011; Almela
et al., 2015; D’Alessandro et al., 2013; Delves et al., 2012b; Duffy
and Avery, 2012; Lelie`vre et al., 2012; Lucantoni et al., 2013; Mi-
guel-Blanco et al., 2015;Ruecker et al., 2014;Sunet al., 2014; Ta-
naka et al., 2013), most of them are not adapted for very large
chemical libraries due to multiple purification steps or lower
throughput formats. In addition, some assays rely on the use of
gametocyte reporters that may restrict their use to genetically
modified parasites (Adjalley et al., 2011; Peatey et al., 2011).
Here we describe high-throughput assays that overcome theseuthors
Figure 1. Induction and Development of Pure, Stage-Specific Gametocytes
(A) Gametocyte production protocol. To create stages I–IV, all steps were performed, but to create stage V only, steps indicated by red boxes were omitted.
(B) Simplified schematic flow chart for the SaLSSA gametocyte assay.
(C) Giemsa smears of gametocytes of stage I-V and gametocyte counts and percentages for each stage based on their morphology (numbers pooled from
multiple cycles).
(D)Zprimevalues for thedifferentgametocyte stagesandassayprotocols. 1384-well TSSA,stages I-V, 2384-well-SaLSSA, stages I-V, 31,536-wellSaLSSA, stageV.
(E) Displayed is the number of viable stage V gametocytes in a dilution series over time (0.5 hr until 6 hr). These data were acquired using stage V gametocytes and
1,536-well SaLSSA (R2 > 0.99).issues. We apply the assays to characterized and uncharacter-
ized chemical libraries. Our analysis reveals features of chemical
compounds that are likely to blockmalaria transmission andmay
serve as starting points for unique transmission-blocking drugs.
RESULTS
Developing an Assay to Identify Compounds with
Transmission-Blocking Activity
Production of Homogeneous Populations of
Gametocytes
To create a homogeneous, stage-specific gametocyte popula-
tion, we optimized a previously described protocol (FivelmanCell Hostet al., 2007) and induced gametocytogenesis in asexual, triple
synchronized P. falciparum NF54 parasites by high parasitemia
and partly spent media (Figure 1A; Experimental Procedures).
Microscopic staging of gametocytes collected over the
12 days of development according to description by Carter
and Miller (1979) showed purities upward of 75% per stage (Fig-
ure 1C) with a reproducible parasitemia of 1.2%–1.6% over the
screening period (data not shown).
Measuring Viability in Non-Replicating Parasites
To detect viability, we used the dye MitoTracker Red CMXRos
(MTR Red), which fluoresces at 600 nm in parasites with intact
mitochondrial membrane potential (Pendergrass et al., 2004;
Poot et al., 1996) (Figure 1B). Parasites were detected using& Microbe 19, 114–126, January 13, 2016 ª2016 The Authors 115
automated microscopy and showed a good correlation (R2 =
0.99) between the number of viable parasites added per well
and the number of MitoTracker Red CMXRos positive objects
(Figure 1E).
Reduction in Number of Liquid-Transfer Steps
To reduce the number of liquid transfer steps and make the
assay more robust and less costly for use with large, unbiased
libraries, we experimented with the use of saponin, an amphi-
pathic glycoside that creates pores in red cell membrane bila-
yers, leading to red cell lysis (Baumann et al., 2000). We found
that treating gametocyte cultures with 0.13% saponin caused
red blood cells in serum-free media to lyse, simplifying the iden-
tification of parasites with automated microscopy. Gametocytes
at a parasitemia of 0.5% to 0.75% and a hematocrit of 1.25%
created a monolayer on the bottom of the well. After MTR Red
staining 1,000 objects could be counted per DMSO control
well (1,536) (Figure 1E). This allowed compound exposure and
imaging in the same plate without an additional transfer step.
We refer to this serum-free one-step protocol as Saponin-Lysis
Sexual Stage Assay (SaLSSA). We found SaLSSA to be more
sensitive to few compounds like the amino alcohols (see below).
Thus, an older, serum-containing assay (two-step sexual stage
assay or TSSA) was used in some cases.
Assay Evaluation
The quality of the assay was found to be robust at all gametocyte
stages: Z prime scores calculated with infected, DMSO-treated
red blood cells and uninfected red blood cells ranged from
0.71 to 0.80 for the one-step protocols (Figure 1D). We evaluated
the fluorescence intensity over time and did not observe signifi-
cant differences between 30 and 360 min (data not shown).
Evaluation of Known Antimalarial Drugs Shows Only
Few Compounds with Activity against Late-Stage
Gametocytes
To further benchmark SaLSSA, we evaluated 50 compounds
currently used as antimalarials or antimalarial tool compounds
(Delves et al., 2012a) in dose response against individual game-
tocyte stages. EC50 values of different chemical classes showed
distinct patterns of activity for the different gametocyte stages as
summarized below (Tables 1 and S1). Most compounds yielded
higher EC50 against stage V gametocytes.
Endoperoxides
Endoperoxides were characterized by low nM EC50 values for
stages I–IV with most failing to generate a dose-response curve
for stage Vs, in agreement with standard membrane-feeding
data: Although DHA, artesunate, and OZ439 have been reported
to have some activity in standard membrane-feeding assays
(SMFAs) (Bolscher et al., 2015; Delves et al., 2012a), none
completely eliminated oocysts at 100 nM, and only OZ439 elim-
inated oocysts at 1 mM, a concentration well above the concen-
trations in bloodwhen being used against blood-stage infections
(Bolscher et al., 2015). Interestingly, these results correlate well
with previous publications reporting that hemoglobin digestion
ends at stages III to IV (Hayward, 2000; Lang-Unnasch and Mur-
phy, 1998), supporting the endoperoxides’ activity against this
process (Klonis et al., 2011).
4-Aminoquinolines
The 4-aminoquinolines (chloroquine, piperaquine, pyronaridine,
napthoquine, hydroxychloroquine, and AQ13) demonstrated116 Cell Host & Microbe 19, 114–126, January 13, 2016 ª2016 The Alow nM EC50 values for stages I and II but showed a drop-off in
activity beginning in stage III and were ineffective against stage
Vs. It is generally thought that 4-aminoquinolines interfere with
the formation of hemozoin, resulting in the death of the parasites,
and previous reports have shown that chloroquine is only active
against early-stage gametocytes (Sinden, 1982) in line with low
activity in SMFAs (Bolscher et al., 2015).
8-Aminoquinolines
The 8-aminoquinolines showed consistent but high (mM) EC50
values across all gametocyte stages. Primaquine, the only
drug approved for blocking transmission, exhibited a 6.5 mM
EC50 against stage V gametocytes in vitro. Tafenoquine, a prima-
quine derivative, had an EC50 of 2.4 mM against stage V gameto-
cytes. The substantially higher EC50 than the ED50 values were
expected because 8-aminoquinolines need to be metabolized
for activity. The mechanism of action of primaquine as well as
the identity of the active metabolites remains unknown.
Amino Alcohols
Amino alcohols are not used to prevent transmission, but some
amino alcohols (lumefantrine, mefloquine, and halofantrine, but
not quinidine and quinine) showed activity across all stages us-
ing SaLSSA. We note, however, that this sensitivity could be
completely reversed by the addition of human serum to cultures
during compound incubation using the TSSA. Mefloquine only
shows SMFA activity at high concentrations (10 mM), 203
above the asexual growth inhibition values (50 nM). Testing
some compounds in the presence of human serumwould be ex-
pected to give more accuracy and eliminate false positives, but
at the expense of efficiency.
Other Clinically Relevant Compounds
The antifolates and sulfonamides, which interfere with nucleic
acid synthesis and include dihydropteroate synthase (DHPS)
and dihydrofolate reductase (DHFR) inhibitors (pyrimethamine,
P218, and chlorproguanil), were inactive across all gametocyte
stages, except for chlorproguanil, which had mM EC50 values
against all stages. Antibiotics used to treat malaria, such as
doxycycline and azithromycin, which act against the apicoplast,
were also inactive. As expected (Fleck et al., 1996), atovaquone
was inactive (Table 1). Evidence that this compound has some
transmission-blocking activity in animals after repeated expo-
sure (Blagborough et al., 2013) may be because it inhibits ooki-
nete formation (Delves et al., 2012a).
Antimalarial Compounds with Stage V Activity
Some antimalarial compounds that are not used in humans did
show activity against stage V gametocytes in our assay (Table 1).
Thiostrepton is a macrocyclic thiopeptide antibiotic that inhibits
prokaryotic translation (Harms et al., 2008) and has been reported
to dually target the proteasome and apicoplast (Aminake et al.,
2011). Thiostrepton had mM EC50 values at all stages. The mode
of actionofmethylene blue remains controversial, but itmay inhibit
glutathione reductase (Buchholz et al., 2008) or hemozoin forma-
tion (Adjalley et al., 2011). It showed low nMEC50 values for stages
I to IV, with some minor loss of activity at stage V, consistent with
reports that methylene blue reduced transmission by 99% in
SMFAs at 38 nM. Pentamidine, which is clinically used for treat-
ment and prophylaxis of Pneumocystis carinii pneumonia (PCP)
and sleeping sickness but not malaria, inhibited gametocytes of
all stages with an EC50 between 0.39 and 2.14 mM. Its mechanismuthors
Table 1. Well-Characterized Antimalarials Active against Asexual Blood Stages Tested in Dose Response against the Five Gametocyte Stages
Compound Chemical Class
EC50 (mM) ± STD
Oocyst ReductionStage I Stage II Stage III Stage IV Stage V
Artemisinin Endoperoxide 0.024 ± 0.001 0.020 ± 0.010 0.012 ± 0.002 0.037 ± 0.003 >12.500 ± 0.000
Artemisone Endoperoxide 0.003 ± 0.000 0.002 ± 0.000 0.003 ± 0.000 0.004 ± 0.001 >12.500 ± 0.000
Artemether Endoperoxide 0.016 ± 0.006 0.005 ± 0.001 0.006 ± 0.002 0.019 ± 0.004 >12.500 ± 0.000 10 mM: 75%–99%3
Artenimol (Dihydroartemisinin) Endoperoxide 0.006 ± 0.001 0.003 ± 0.001 0.007 ± 0.000 0.021 ± 0.008 >12.500 ± 0.000 1 mM: 90%1
Artesunate Endoperoxide 0.008 ± 0.002 0.004 ± 0.000 0.013 ± 0.003 0.049 ± 0.013 >10.601 ± 2.686 1 mM: 55%1
OZ439 mesylate Endoperoxide 0.011 ± 0.001 0.005 ± 0.000 0.003 ± 0.000 0.002 ± 0.000 >12.500 ± 0.000 1 mM: 100%1
OZ277(RBX-11160) Endoperoxide 0.008 ± 0.001 0.004 ± 0.000 0.002 ± 0.000 0.008 ± 0.003 >12.500 ± 0.000 10 mM: 75%–99%3
Amodiaquine 4-aminoquinoline 0.012 ± 0.001 0.006 ± 0.001 0.096 ± 0.013 2.456 ± 0.757 1.783 ± 0.119 10 mM: 50%–74%3
AQ-13 4-aminoquinoline 0.043 ± 0.002 0.033 ± 0.000 0.484 ± 0.159 6.471 ± 0.888 6.051 ± 1.091 10 mM: 25%–49%3
Chloroquine 4-aminoquinoline 0.096 ± 0.007 0.098 ± 0.005 >6.250 ± 0.000 >6.250 ± 0.000 >6.25 ± 0.000 10 mM: 25%–49%3
Hydroxychloroquine 4-aminoquinoline 0.107 ± 0.011 0.131 ± 0.005 >4.489 ± 2.490 >6.250 ± 0.000 >6.25 ± 0.000 10 mM: 25%–49%3
Naphthoquine 4-aminoquinoline 0.025 ± 0.003 0.014 ± 0.000 0.296 ± 0.078 >4.167 ± 0.000 >4.167 ± 0.000
Piperaquine phosphate 4-aminoquinoline 0.018 ± 0.002 0.014 ± 0.003 0.031 ± 0.007 >4.167 ± 0.000 >4.167 ± 0.000 1 mM: 25%1
Pyronaridine phosphate 4-aminoquinoline 0.013 ± 0.001 0.010 ± 0.002 0.125 ± 0.079 2.579 ± 0.811 2.075 ± 0.031 1 mM: 80%1
Primaquine 8-aminoquinoline 2.467 ± 0.168 2.254 ± 0.236 5.400 ± 1.471 5.151 ± 0.253 6.500 ± 0.955
NPC-1161B 8-aminoquinoline 2.002 ± 0.188 2.023 ± 0.288 3.510 ± 0.013 3.599 ± 0.182 2.865 ± 0.031 10 mM: 100%3
Pamaquine
(diethlyprimaquine)
8-aminoquinoline 1.682 ± 0.318 1.404 ± 0.000 2.411 ± 0.672 2.824 ± 0.250 2.529 ± 1.033
Tafenoquine 8-aminoquinoline 4.560 ± 0.942 3.682 ± 0.871 3.738 ± 0.210 3.484 ± 0.300 2.449 ± 0.262
Mefloquine (+ RS) Amino alcohol* 0.038 ± 0.001 0.039 ± 0.005 0.078 ± 0.013 0.579 ± 0.600 0.158 ± 0.007 10 mM: 100%3
Halofantrine Amino alcohol* 0.002 ± 0.001 0.001 ± 0.000 0.023 ± 0.039 1.50946 ± 2.072 0.007 ± 0.002 10 mM: 75%–99%3
Lumefantrine Amino alcohol* 0.013 ± 0.002 0.013 ± 0.002 0.015 ± 0.006 0.599 ± 0.188 0.052 ± 0.016 1 mM: 60%1
Mefloquine (Racemic) Amino alcohol* 0.044 ± 0.001 0.052 ± 0.006 0.143 ± 0.059 0.818 ± 0.005 0.132 ± 0.003
Quinidine Amino alcohol* 0.138 ± 0.034 0.208 ± 0.007 >9.167 ± 4.714 >12.500 ± 0.000 >11.832 ± 0.945
Quinine sulfate dihydrate Amino alcohol* 0.440 ± 0.039 0.496 ± 0.115 >8.775 ± 5.268 >12.500 ± 0.000 >8.865 ± 5.141
Methylene Blue trihydrate Aromatic 0.020 ± 0.008 0.015 ± 0.005 0.013 ± 0.001 0.012 ± 0.002 0.258 ± 0.029 38 nM: 99%2
Thiostrepton Antibiotic 3.405 ± 0.157 3.373 ± 0.262 2.837 ± 0.232 1.820 ± 0.419 3.261 ± 0.461
Azithromycin Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.236 ± 0.374 >12.500 ± 0.000 >12.500 ± 0.000 10 mM: 0%3
Doxycyclin Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 10 mM: 0%3
Trimethoprim Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000
Cis-Mirincamycin (HCl) Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000
Trans-Mirincamycin (HCl) Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000
Fosmidomycin mono sodium Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000
Clindamycin Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000
Tetracycline Antibiotic >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000
Chlorproguanil hydrochloride Antifolate 9.350 ± 1.506 7.794 ± 0.287 7.869 ± 0.177 5.209 ± 1.107 4.798 ± 0.758
(Continued on next page)
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Table 1. Continued
Compound Chemical Class
EC50 (mM) ± STD
Oocyst ReductionStage I Stage II Stage III Stage IV Stage V
Dapsone Antifolate >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Pyrimethamine Antifolate >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Cycloguanil Antifolate >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Proguanil hydrochloride Antifolate >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
P218.HCl Antifolate >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Sulfadiazine Sulfonamide >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Sulfamethoxazole Sulfonamide >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Sulfadoxine Sulfonamide >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Cycloheximide Other 1.917 ± 0.060 0.640 ± 0.028 0.913 ± 0.027 0.477 ± 0.402 2 92 ± 0.080
Pentamidine Other 0.397 ± 0.040 0.591 ± 0.027 0.697 ± 0.016 0.813 ± 0.177 2 43 ± 0.189
Dehydroepiandrosterone sulfate Other >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Flavin mononucleotid
(Riboflavin)
Other >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
N-acetyl-D-penicillamine Other >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Deferoxamine mesylate salt Other >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
Puromycin Control 0.123 ± 0.069 0.122 ± 0.045 0.103 ± 0.039 0.110 ± 0.038 0 22 ± 0.048
Atovaquone Naphthalene >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 2.373 ± 1.995 >12 00 ± 0.000
GNF179 Imidazolopiperazine 0.341 ± 0.090 0.064 ± 0.017 0.020 ± 0.000 0.009 ± 0.005 0 03 ± 0.001 15 nM: 100%5
KAI407 Imidazopyrazine 0.593 ± 0.079 0.636 ± 0.057 0.415 ± 0.073 0.329 ± 0.043 0 56 ± 0.026
KDU691 Imidazopyrazine 0.532 ± 0.024 0.565 ± 0.009 0.354 ± 0.071 0.237 ± 0.057 0 50 ± 0.001 1 mM: 100%4
KAF246 Spiroindolone 0.001 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.001 0 02 ± 0.001
DDD107498 Quinoline-4-carboxamide 0.003 ± 0.000 0.005 ± 0.002 0.005 ± 0.001 0.002 ± 0.000 0 09 ± 0.002 EC50: 1.8 nm
6
DMSO Control >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12.500 ± 0.000 >12 00 ± 0.000
EC50 is displayed in mM ± SD (SaLSSA, 384 well in duplicate).
*Amino alcohols (lumefantrine) showed little transmission-blocking activity in the presence of human serum (see Table S1).
1Oocyst reductions derived from Bolscher et al. (2015).
2Oocyst reductions derived from Adjalley et al. (2011).
3Oocyst reductions derived from Delves et al. (2012a).
4Oocyst reductions derived from McNamara et al. (2013).
5Oocyst reductions derived from this manuscript.
6Oocyst reductions derived from Baragan˜a et al. (2015).
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Figure 2. Screening of theMMVMalaria Box
in Comparison to GNF179
(A) Structures of MMV665941 and GNF179.
(B) In vitro activity of MMV665941 and GNF179
against stage V gametocytes in dose response
(1,536-well format, SaLSSA in duplicate).
(C) Mean oocyst counts per midgut with gameto-
cytes incubated with DMSO, GNF179 (53 EC50),
and MMV665941 (53 EC50). Experiment was per-
formed in duplicates.
(D) Comparison of all 42 EC50 values below
12.5mMof theMMVmalaria box compounds when
screened against gametocytes stages I, III, and V.
The average EC50 of compounds tested against
stage V gametocytes is significantly higher
compared to stage I gametocytes (p < 0.05,
ANOVA test, Prism 6).ofaction isunknown,although ithasbeenreportedto inhibit hemo-
zoin formation in Plasmodium by interaction with ferriprotopor-
phyrin IX (Bray et al., 2003; Stead et al., 2001).
Compounds in Clinical Development
Newer classes of compounds in development, including the spi-
roindolones (Rottmann et al., 2010), imidazolopiperazines (Meis-
ter et al., 2011), imidazopyrazines (McNamara et al., 2013), and
quinoline-4-carboxamides (Baragan˜a et al., 2015), all have re-
ported transmission-blocking activity, and members of these
compound classes were tested using SaLSSA (Table 1).
KAF246, a spiroindolone closely related to the clinical candidate
KAE609 (also known as cipargamin or NITD609) that acts against
the plasma membrane ATPase PfATP4 (Rottmann et al., 2010),
showed the expected activity (EC50 = 1 to 2 nM). GNF179, an imi-
dazopiperazine closely related to the clinical candidate KAF156
(Kuhen et al., 2014), showed the expected low nanomolar activity
in the SaLSSA and complete transmission-blocking activity in
SMFAs at physiologically relevant concentrations of 15 nM (Fig-
ures 2A–2C). The PI(4)K-inhibitor KDU691, which inhibits trans-
mission at 1 mM in SMFAs (McNamara et al., 2013), had submi-
cromolar EC50 values across all five gametocyte stages, similar
to the values seen against blood stages (200 nM). The Plasmo-
dium falciparum translation elongation factor 2 (eEF2)-inhibitor,
DDD107498, likewise showed potent activity, in line with re-
ported activity in other cellular and standard membrane feeding
assays (Baragan˜a et al., 2015).
Library 1: MMV Malaria Box Contains Transmission-
Blocking Compounds
To determine whether the loss of activity against stage V para-
sites was typical or reflects the historical focus on compoundsCell Host & Microbe 19, 114–126derived from quinine and artemisinin,
400 compounds from the MMV malaria
box were examined (Spangenberg et al.,
2013). These compounds, which were
all identified in asexual blood stage
screens, were first examined at a single
dose of 12.5 mMagainst each gametocyte
stage with TSSA. As expected, the high-
est number of compounds were activeagainst early-stage gametocytes: 216 compounds inhibited the
viability of stage I gametocytes by more than 70%, 78 com-
pounds inhibited stage III gametocytes, and 79 compounds in-
hibited stage V gametocytes (Table S2).
Dose-response analysis against stage I, III, and V gameto-
cytes for the 50 most active compounds confirmed activity
<5 mM for 28 of the 50 compounds with the TSSA. EC50 values
for stage V were significantly higher than for stage I gametocytes
for 42 of the 50 compounds (Figure 2D). A few compounds
showed EC50 values of %1.5 mM against stage V gametocytes
in both TSSA and SaLSSA (Table S2), including MMV665941
(stage V EC50 1.04 mM, SaLSSA, Figure 2B) followed by
MMV019918 (stage V EC50 1.46 mM, SaLSSA). SMFA studies
with MMV665941 using GNF179 as a control at a concentration
of five and ten times the EC50 calculated from the above
described stage V gametocyte assay showed that mosquitoes
fed on the compound-exposed gametocytes had no oocysts in
their midguts, whereas the DMSO control group did (Figure 2C),
most likely because the compound-treated gametocytes did not
exflagellate (data not shown).
We further investigated a subset of 18 compounds (Table 2)
with reported activity against gametocytes (Bowman et al.,
2014; Duffy and Avery, 2013; Ruecker et al., 2014; Sun et al.,
2014) and available luciferase-SMFA data using 1,536-well
SaLSSA against gametocytes stages I, III, and V. Of this control
set, 14 of the 18 were active in at least one stage in SaLSSA with
an EC50 of less than 10 mM, and 13 of the 14 were active in
SMFAs (Figure S3; Table S5). A possible false-negative com-
pound was MMV665882 (Figure S3G), which showed an incom-
plete curve in SaLSSA but little activity in the SMFA. This
compound showed some activity in viability readouts by others
(Duffy and Avery, 2013; Sun et al., 2014). The four potential false, January 13, 2016 ª2016 The Authors 119
Table 2. Activity of 18 MMV Control Compounds against Sexual and Asexual Stages
Compound
Viability INDEX EC50 (mM)
Stage I Stage II Stage III Stage IV Stage V Stage Asex Stage I Stage III Stage V
MMV000442 0.120 0.192 0.385 0.633 0.442 0.362a 0.553 ± 0.041 >10.000 ±0.000 >10.000 ±0.000
MMV665971 0.056 0.097 0.137 0.171 0.416 0.489a 0.746 ± 0.116 >10.000 ±0.000 >10.000 ±0.000
MMV011438 0.005 0.005 0.015 0.000 0.000 0.327a, 0.332b 1.120 ± 0.116 2.428 ±0.620 4.225 ±0.609
MMV000248 0.006 0.057 0.061 0.085 0.121 0.719a 1.058 ± 0.026 3.074 ±0.533 3.700 ±0.173
MMV666125 0.006 0.002 0.071 0.196 0.234 0.381a, 2.844b 0.094 ± 0.068 1.342 ±0.259 6.154 ±0.569
MMV019918 0.017 0.014 0.010 0.015 0.033 0.800a 1.264 ± 0.145 0.576 ±0.069 1.463 ±0.296
MMV019266 0.028 0.014 0.035 0.082 0.066 0.615a 0.935 ± 0.214 1.372 ±0.210 1.743 ±0.206
MMV396797 0.034 0.007 0.033 0.094 0.077 0.477a 5.435 ± 0.470 2.094 ±0.424 3.477 ±0.175
MMV667491 0.037 0.048 0.034 0.032 0.000 1.230a 0.980 ± 0.069 0.667 ±0.101 0.596 ±0.085
MMV019881 0.063 0.065 0.039 0.047 0.013 0.646a 3.048 ± 3.278 8.408 ±1.577 0.721 ±0.141
MMV000448 0.066 0.016 0.083 0.201 0.231 0.235a, 0.033b 1.195 ± 0.113 5.356 ±0.612 4.652 ±0.394
MMV665882 0.116 0.092 0.122 0.168 0.130 0.466a 0.180 ± 0.036 1.477 ±0.136 0.984 ±0.022
MMV665941 0.157 0.020 0.095 0.061 0.110 0.255a 0.388 ± 0.035 2.271 ±0.751 1.044 ±0.040
MMV665980 0.240 0.184 0.087 0.108 0.247 0.211b >10.000 ± 0.000 9.350 ±3.237 6.612 ±1.100
MMV007116 0.377 0.505 0.734 0.733 0.846 0.351a, 0.716b >10.000 ± 0.000 >10.000 ±0.000 >10.000 ±0.000
MMV665827 0.592 0.900 0.810 0.769 0.791 0.119a, 0.166b >10.000 ± 0.000 >10.000 ±0.000 >10.000 ±0.000
MMV666021 0.610 0.871 0.740 0.897 1.055 0.094a, 1.998b >10.000 ± 0.000 >10.000 ±0.000 >10.000 ±0.000
MMV020492 0.768 0.756 0.970 0.912 0.989 0.026a >10.000 ± 0.000 >10.000 ±0.000 >10.000 ±0.000
The viability index shows the ratio for each gametocyte stage (I–V) compared to DMSO-treated control wells screened at 12.5 mM (384-well TSSA).
EC50 values for stage I, III, and V, gametocytes are displayed as mean ± SD (1,536-well SaLSSA, in duplicate). Asexual stage data for 3D7 parasites
as provided by MMV and the ChEMBL-NTD repository (https://www.ebi.ac.uk/chemblntd).
a72 hr DAPI assay (Duffy and Avery, 2012).
b72 hr SYBR green assay (Meister et al., 2011).positives included MMV020492 (Figure S3A), which was previ-
ously reported to have low activity against male gametes
(Ruecker et al., 2014) but gave no inhibition in SMFAs and was
inactive in SaLSSA. Two other false positives were
MMV665827 (Figure S3C) and MMV007116 (Figure S3D), which
had been shown to reversibly inhibit male gamete formation
(Ruecker et al., 2014). The fourth compound, MMV666021 (Fig-
ure S3B), which had been reported active in luciferase assays
with late-stage gametocytes (Duffy and Avery, 2013), showed
some inhibition in the single-point studies but was not recon-
firmed in dose response. This compound was weakly active in
luciferase-based SMFAs (complete inhibition at 10 mM, partial
at 1.6). The reasons for the discrepancies for this compound
are unclear, but it is possible that compound source, solubility,
or parasite genetic background could play a role, especially as
literature-reported blood-stage values (3D7) vary from 90 nM
to 2 mM.
Library 2: GNF Malaria Box
To further investigate the rate at which transmission-blocking
compounds would be identified in sets of compounds with
known blood-stage activity (EC50s of less than 10 mM), we inves-
tigated the GNF malaria box (Plouffe et al., 2008). This set of
3,558 compounds was created after screening proliferating
asexual parasites at a final compound concentration of
1.25 mM. The set was screened at a single concentration of
1.25 mMagainst stage V gametocytes with the 384-well SaLSSA.
Of these, 145 compounds (4.07%) inhibited stage V gameto-
cytes at greater than 72.3% (Figure S1A). Dose-response anal-120 Cell Host & Microbe 19, 114–126, January 13, 2016 ª2016 The Aysis showed 108 of the 145 compounds reconfirmed as having
activity of less than 1 mMwith 22 compounds giving EC50 values
below 100 nm against stage V gametocytes. Unlike the clinical
antimalarials (Table 1), most of which showed a steep drop-off
in activity with mature gametocytes, these scaffolds were almost
all equipotent against asexual blood stages and stage V gameto-
cytes. Some of the most active scaffolds (Figure S1B) were
carbamazide thioureas (Klayman et al., 1979) aswell as naphtho-
quinones, a compound class known to be active against game-
tocytes (Tanaka et al., 2015). Several of these scaffolds were
also active against a P. yoelii hepatocyte development and inva-
sion assay (Meister et al., 2011) that predicts causal prophylactic
activity (Figure S1C; Table S3).
Library 3: Broad Diversity-Oriented Synthesis Library
In order to determine the fraction of active compounds that
would be found in a larger library that was not preselected for ac-
tivity against asexual parasites, we tested compounds from the
diversity-oriented synthesis (DOS) library (Dandapani and Mar-
caurelle, 2010). This library was designed to populate chemical
space broadly with small molecules having both skeletal and ste-
reochemical diversity (Schreiber, 2000).
Two sets of compounds from the DOS compound library were
screened against stage V using 1,536-well SaLSSA at 2.5 mM in
duplicate (Figure S2A). The first was an ‘‘informer set,’’ which in-
cludes 9,886 compounds selected to represent a sampling of the
structural diversity of all of the DOS scaffolds while also
capturing preliminary structure-activity relationships (SARs)
and stereochemical structure-activity relationships (SSARs). 25uthors
compounds inhibited stage V gametocytes in both replicates by
>30% (Table S4, hit rate 0.25%), and 17 were inconclusive
(active in one of two replicates). To reconfirm and investigate
the SARs as well as SSARs, 41 compounds were retested in
dose-response along with 37 stereoisomers and seven analogs
of select compounds. 13 of the hits and one inconclusive ex-
hibited EC50s < 5 mM upon retest, resulting in a retest rate of
23% (or 54% for hits only).
A second compound set included 89 compounds (represent-
ing 17 scaffolds) that had previously been shown to have activity
in a blood-stage assay against P. falciparum Dd2 (EC50 < 2 mM;
N.K., unpublished data). These compounds had not been further
assessed for mechanism of action or additional stage-specific
activity against Plasmodium prior to this study. An identical
screening pipeline was used for the blood-stage active com-
pounds; in this case, 15 compounds were identified as hits (hit
rate 16.9%). These hits and two additional stereoisomers were
retested at dose-response, whereupon ten of the compounds
exhibited EC50s < 5 mM (retest rate 67%).
Taken together, the 35 hits encompassed 12 different scaf-
folds, with five singletons and seven scaffolds with two or
more representatives. Representatives from six of these scaf-
folds are shown in Figure S2C; one scaffold was eliminated
due to a lack of SSARs and SARs in the hits. While the activity
needs to be validated with resynthesized compounds, some
of these do show interesting patterns of activity, including
one compound with greater activity against gametocytes
(BRD0608), four compounds with activity across all three para-
site stages, and one compound (BRD1260) with activity against
just gametocytes and the asexual blood stages (Figure S2B).
Additional studies will be of interest to validate these data and
investigate the mechanisms of action of these compounds.
Cheminformatic Compound Clustering
To further validate the screens and to identify compounds that
can serve as starting points for the development of the transmis-
sion-blocking drugs, all compounds that had been screened
were hierarchically clustered based on their scaffold similarity.
We then identified clusters of structurally related compounds
that showed enrichment in the sexual-stage active set at rates
higher than expected by chance (Figure 3). For example, a clus-
ter with the highest enrichment score (enrichment log10p =
16.11) consists of 13 compounds related to GNF-Pf-3202
and GNF-Pf-3600 (dioxonapthalen-acetamides), with 10 out of
13 compounds being active in the gametocyte assay. Another
enriched cluster contains 21 compounds structurally similar to
GNF-Pf-5511 and GNF-Pf-5386 (tetrahydroisoquinoline-4-car-
boxamide scaffolds that are related to the PfATP4 inhibitor,
(+)-dihydroisoquinolones, (+)-SJ733) with seven of the 21 com-
pounds being active (log10p = 7.01). This is not unexpected,
given that other PfATP4 inhibitors are active against late-stage
gametocytes and (+)-SJ733 potently blocks transmission (Jime´-
nez-Dı´az et al., 2014). A final scaffold family that is highly over-
represented contains four of the five 2-furancarboxamides
(GNF-Pf-1329, GNF-Pf-3542, GNF-Pf-783, GNF-Pf-1696, and
GNF-Pf-2740) in the library (log10p =7.35), all of which showed
moderate activity against stage V gametocytes (0.61 to
0.484 nM) but weaker activity against asexual blood stage para-
sites (1.72 to > 10 mM). To our knowledge, this compound classCell Hosthas not previously been associated with blocking transmission.
These data suggest that screens of very large libraries will likely
yield starting points for the discovery of transmission-blocking
drugs.
DISCUSSION
The present data differ from those that have been reported by a
number of other laboratories. Some assays have shown that
compounds such as artemether and OZ439 have late-stage ga-
metocytocidal activity of less than 1 mM (Bolscher et al., 2015;
Duffy and Avery, 2013). The consensus is that mature gameto-
cytes are resistant to endoperoxides (Delves, 2012; Peatey
et al., 2011). Most previous reports combined gametocyte
stages for late-stage gametocyte testing (stages III-V or IV-V),
which might account for conflicting compound activity (Duffy
and Avery, 2013; Lelie`vre et al., 2012; Peatey et al., 2011; Sun
et al., 2014). Another consideration is that the readout of different
gametocytocidal assays might vary with the mode of action of
certain drugs, depending on which biological pathway the spe-
cific assay is interfering with (Reader et al., 2015).
Overall, our data suggest that low-cost SaLSSA gives few, if
any, false positives, compared to available SMFA data. On the
other hand, the SaLSSA assay may give a few false-negatives,
and will likely miss reversible inhibitors of gamete formation.
In the majority of cases, our data showed that stage V game-
tocytes had a lower susceptibility to compounds than stage I ga-
metocytes, suggesting decreased metabolic activity during their
maturation in preparation for subsequent development in the
mosquito midgut. The acquired standard membrane-feeding
data, which still represent the gold standard for transmission-
blocking activity, suggest that compounds that inhibit stage V
gametocytes can block transmission as well. On the other
hand, the SMFAs may also find compounds that our cellular
assay would miss, including compounds that have a contracep-
tive effect. Given that fertilization occurs in the mosquito midgut
over minutes while late-stage gametocytes can persist in the hu-
man body for days, stage V gametocytes are arguably more
attractive therapeutic targets.
The data from this study indicate which proteins and path-
ways might be targeted by transmission-blocking drugs (Fig-
ure 4). Compounds that interfere with hemoglobin digestion
would be poor candidates for transmission-blocking drugs,
although they could yield a reduction in gametocyte numbers
as early-stage gametocytes might be killed. In addition, the
process of DNA replication should probably not be targeted,
nor apicoplast function (azithromycin and doxycycline). Targets
for compounds that act against mature gametocytes include
proteins that play a role in protein translation (the targets of
puromycin, DDD107498, cycloheximide, thiostreptin) and pro-
cessing, including protein secretion (GNF179), as well as pro-
tein degradation (e.g., epoxomycin; Czesny et al., 2009). Inter-
estingly, functional genomic studies had previously shown that
gametocytes acquire and store RNA transcripts that rapidly
convert to proteins during gamete formation (Mair et al.,
2006), creating a particular vulnerability. Targets involved in
maintaining ion homeostasis, such as PfATP4 as well as lipid
kinases (e.g., PI4K), are transmission-blocking targets as well
as asexual stage targets.& Microbe 19, 114–126, January 13, 2016 ª2016 The Authors 121
Figure 3. Starting Points for Transmission-Blocking Drugs
All compounds in this study were clustered by their substructure similarity. All compounds with the same substructure (Tanimoto average compound similarityR
0.85) were assigned to different scaffold families (indicated by different colors). Non-active compounds are shown as circle nodes and gametocyte-active
compounds as diamonds. LogP is log probability of enrichment in the stage V gametocyte active set relative to rate expected by chance for each scaffold family.
EC50 values are for stage V gametocytes SaLSSA 1,536-well format.It should be noted that all these targets are also essential for
asexual parasites. Targeting exclusively gametocytes could be
achieved through inhibiting translational repression, autophagy,122 Cell Host & Microbe 19, 114–126, January 13, 2016 ª2016 The Asperm function, as well as meiosis. It is expected that com-
pounds inhibiting these processes would be found at lower rates
in large libraries, emphasizing the need for ultra-high-throughpututhors
Figure 4. Druggable Organelles and Pro-
cesses in Gametocytes
Infected red blood cell (red) with mature gameto-
cyte (blue) and parasitophorous vacuole (white) as
well as schematic parasite organelles known as
P. falciparum drug targets. The upper (left) section
displays compounds with similar activity against
stage V gametocytes (SaLSSA) and asexual blood
stage parasites as well as their presumed mode of
action. The lower (right) section lists compounds
with not active against stage V gametocytes
compared to asexual blood stage parasites.
Ery: erythrocyte; Gam: gametocyte; PPM: parasite
plasma membrane; PV: parasitophorous vacuole;
PVM: parasitophorous vacuole membrane.screens. One example is BRD0608, whose EC50 against asexual
blood stages was 153 higher than against stage V gametocytes
and whose selectivity for sexual stages might be improved
through medicinal chemistry.
The advantage of compounds like BRD0608 is a reduced po-
tential for emergence of drug resistance. There are billions of
asexually replicating parasites in an infected human, each of
which has the capacity to develop a drug resistance mutation
and pass it on to their progeny. This has been a major reason
why malaria control is so difficult.
An open ethical question is whether drugs, which do not
relieve malaria symptoms but benefit the community as a whole,
should be licensed. Vaccines may be given that provide little
benefit to an individual—for example, the rubella vaccine in
boys, mainly recommended to cohort-protect pregnant women
in order to prevent congenital rubella syndrome of newborns.
Vaccines are also not without risk, and one could argue that
the benefit to humanity that would be achieved with malaria
eradication would outweigh the risk.
EXPERIMENTAL PROCEDURES
Gametocyte Culture
Asexual P. falciparum parasites (NF54) were grown at 5% hematocrit in O+ hu-
man erythrocytes in serum-containing complete media (RPMI 1640, genta-
micin 0.05 mg/ml, hypoxanthine 0.014 mg/ml, HEPES 38.4 mM, sodium bicar-
bonate 0.2% [w/v], D-glucose 0.2% [w/v], sodium hydroxide 3.4 mM, 4.3%
[w/v] heat-inactivated human serum [O+] and 0.2% [w/v] AlbuMAX II) at
37C under low-oxygen conditions (3%O2, 5% CO2, and 92%N2) and a para-
sitemia between 0.5% and 3%. Ring-stage parasites were triple synchronized
(d-8, d-6, d-4) with 5% (w/v) D-Sorbitol, and cultures were expanded from T25
to T225 culture flasks. The hematocrit was adjusted to 5%until day4. On day
2, only 50% fresh media was substituted during a high parasitemia of 7%–Cell Host & Microbe 19, 114–12610%.Media was exchanged daily from day1 on-
ward. For stages I–IV, magnetically activated cell
sorting (MACS) was performed on day 0 and
cultures were sorbitol synchronized on day 1. All
gametocytes were treated with 50 mM NAG on
days 0–9. See Supplemental Experimental Proce-
dures for more details.
Compound Assays
Gametocyte stages I–V were diluted to 0.50%
gametocytemia and 1.25% hematocrit into com-
plete media for the two step protocol (TSSA) or
0.5%–0.75% gametocytemia and 1.25% hemato-crit into serum-free SALSSA screening media (RPMI 1640, gentamicin
0.05mg/ml, hypoxanthine 0.014mg/ml, HEPES 38.4mM, sodium bicarbonate
0.2% [w/v], D-glucose 0.2% [w/v], sodium hydroxide 3.4mM and 0.4% [w/v]
AlbuMAX II). Cultures were dispensed (40 ml versus 10 ml) into 384 or 1,536-
well plates containing 50 nl or 2.5 nl of compound (final concentration of 1.25
to 12.5 mM) using a MultiFlo dispenser. Plates were incubated at 37C for
72 hr under low-oxygen conditions. For SaLSSA 3 ml (1,536 well) or 10 ml (384
well) of 2.5 mMMitoTracker Red CMXRos and 0.13% saponin solution (w/v) in
screening media was added to each well, and plates were incubated for 60–
120 min at 37C. For 384-well TSSA, 5 ml MitoTracker Red CMXRos (5 mM) in
screening media was added to each well. After 20 min at 37C, 5 ml was trans-
ferred from the assay plate to a new 384-well imaging plate, that already con-
tained 40 ml MitoTracker Red CMXRos (500nm) in serum-free screeningmedia.
For both TSSA and SaLSSA, plates were imaged after 30 min incubation.
High-Content Imaging and Analysis
Imaging of 384- or 1,536-well plates was performed using a high content im-
aging system (Operetta, Perkin Elmer) and Harmony software for image anal-
ysis. Viability indices were calculated by dividing the particle count of each
compound-treated well by the average particle count of the DMSO wells per
plate and range from 0 (active compound) to >1 (inactive). Z values were calcu-
lated using DMSO-treated gametocytes as positive and uninfected red blood
cells as negative wells.
SMFA—Traditional
P. falciparum NF54 parasites were grown at 0.5% parasitemia and 5% hemat-
ocrit and continuously cultured with daily media changes until they reached
stage V (Gregory et al., 2012). After incubation for 24 hr with compound in
DMSO, the SMFA was performed (Gregory et al., 2012). Briefly, 4- to 6-day-
old female A. stephensi STE 2 mosquitoes were fed with the treated gameto-
cytes for 15 min using a membrane feeding apparatus. Midguts were
dissected after 8 days, and the number of oocysts counted.
SMFA—Luciferase
P. falciparum NF54-L1 (hsp70-luc reporter) stage V gametocytes were pre-
incubated for 24 hr with compound in six dilutions in duplicate. DMSO was, January 13, 2016 ª2016 The Authors 123
used as negative and DHA as positive control. The compound was washed
out, and the gametocytes were fed to Anopheles stephensi mosquitoes. At
day 8 post-infection, luminescence signals were determined for 24 individual
mosquitoes per cage. EC50s were determined by applying a four parameter lo-
gistic regression model. The SMFAs, which were organized by a consortium of
laboratories including this one, have been deposited at ChEMBL-NTD (https://
www.ebi.ac.uk/chemblntd) and were performed by TropIQ in Nijmegen, The
Netherlands.
P. berghei Liver Stage Invasion Assay
Liver stage assays were performed as previously described (Baragan˜a et al.,
2015). Briefly, 103 P. berghei luciferase-expressing sporozoites (New York
University Insectary) were used to infect HepG2-A16-CD81EGFP cells (pre-
treated with compound at 1.25 mM) in a 1,536-well plate. After incubation
for 48 hr, 2 ml BrightGlo (Promega) was added, and the EEF growth was
quantified by bioluminescence on an Envision Multilabel Reader
(PerkinElmer).
Compound Clustering
13,844 tested compounds were clustered using the Scaffold Tree algorithm
(Schuffenhauer et al., 2007). Each scaffold node was then assigned an enrich-
ment score reflecting the degree of overrepresentation of active compounds
(stage V gametocyte inhibitors). We calculated the accumulative hypergeo-
metric p value as probability of observing at least as many hits as we observed
within each scaffold. The tree was then pruned, so that only scaffolds with p
values < 0.001 were retained. The final resultant tree in Figure 3 was rendered
with Cytoscape (version 3.2.0). To focus on those nodes where the scaffold of
a node could reasonably resemble the full structures of all associated com-
poundmembers, the average Tanimoto similarity score between each scaffold
node and its associated compounds were calculated based on ChemAxon to-
pological fingerprints (ChemAxon, Kft.), and those tree nodes and leaves with
at least 0.85 Tanimoto scores and with at least three hits are highlighted in
colors in Figure 3.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, five tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chom.2015.12.001.
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